ANTIBE THERAPEUTICS INC - ATBPF STOCK NEWS

Antibe Therapeutics Inc. (OTCQX: ATBPF) reported positive advancements in its drug candidate, otenaproxesul. Recent animal studies confirm rapid drug uptake, supporting its potential for effective pain management. The company aims for its first clinical dose in Q3 2023, with top-line data expected within a year. As of December 31, 2022, Antibe held $42.4 million in cash, providing over two years of operational runway. Additionally, they have transitioned to a faster-dissolving formulation for otenaproxesul, enhancing safety and efficacy for acute pain. Key upcoming milestones include the initiation of clinical studies in 2023.

Antibe Therapeutics Inc. (OTCQX: ATBPF) reported its fiscal quarter results for September 30, 2022, noting significant advancements in its drug otenaproxesul, including a new faster-dissolving formulation and extended IP protection until 2042. The company sold its Citagenix subsidiary for $6.5 million in cash, enhancing funding without shareholder dilution. Antibe ended the quarter with $45.4 million in cash, ensuring over two years of financial runway. The net loss decreased to $6.1 million from $8.7 million in the prior quarter, reflecting improved R&D expenditure of $3.9 million.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) has finalized the sale of its subsidiary Citagenix Inc. to HANSAmed Limited for $6.5 million, providing non-dilutive funding to advance its drug development pipeline. The transaction includes a guaranteed payment of $3.5 million, with the potential for an additional $3 million based on sales milestones. This deal strengthens Antibe's balance sheet and focuses its strategy on developing non-opioid therapies. The lead drug, otenaproxesul, is aimed at treating acute pain, while the company also plans to target inflammatory bowel disease.

Antibe Therapeutics Inc. (OTCQX: ATBPF) has filed a patent application for an enhanced formulation of its lead drug, otenaproxesul, extending its intellectual property protection to 2042. This new formulation is expected to provide a faster onset of action and allow for lower dosing, improving safety and efficacy in treating acute pain.

Antibe will no longer pursue a Phase II molar study, opting instead for reduced-cost animal studies followed by a Phase II bunionectomy study scheduled for H1 2023, optimizing its clinical development path.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) held its annual meeting of shareholders, where all resolutions were approved. Key points included the election of directors, with Robert E. Hoffman receiving 89.12% support, and Roderick Flower achieving 94.91%. The company aims to develop safer therapies targeting inflammation, focusing on its lead drug, otenaproxesul, as an alternative to opioids. Voting results are available on SEDAR.

Antibe's pipeline also includes ATB-352, targeting specialized pain, and future goals include developing treatments for inflammatory bowel disease.

Antibe Therapeutics Inc. (ATBPF) will present clinical data on otenaproxesul's efficacy in treating acute pain at the PAINWeek National Conference from September 6-9 in Las Vegas. The study demonstrated otenaproxesul’s potent anti-inflammatory effects, notably its ability to reduce white blood cell infiltration. With its Phase II program commencing this month, Antibe aims to position otenaproxesul as a safer alternative to NSAIDs and opioids amid the ongoing opioid crisis. Full results will be available on Antibe's website following the presentation.

Antibe Therapeutics Inc. (OTCQX: ATBPF) announced its financial results for the quarter ended June 30, 2022. The company reported a net loss of $5.5 million but retains a strong cash position of $50 million, providing over two years of operational runway. Antibe is set to initiate a Phase II trial for its lead drug, otenaproxesul, targeting acute pain in September 2022. Additionally, the company is advancing its inflammatory bowel disease program and has signed an agreement to sell Citagenix for $6.5 million. Upcoming milestones include trial results expected early in 2023.

Antibe Therapeutics Inc. has announced its financial results for the fiscal year ended March 31, 2022. The company holds $55 million in cash, ensuring over two years of financial runway. Antibe is advancing its lead drug, otenaproxesul, through a Phase II program targeting acute pain, with developments planned for bunionectomy and molar extraction trials. The company also reported a net loss of $25.1 million for the fiscal year, slightly improved from $26.3 million last year.

Antibe Therapeutics Inc. (OTCQX: ATBPF) announces a Warrant Extension and Amended Exercise Price for 3,117,957 common share purchase warrants. The exercise price is reduced to $1.80 per share, and the expiry date is extended to December 31, 2023. Conditional approval from The Toronto Stock Exchange was granted for these amendments. Antibe is focused on developing safer therapies targeting inflammation with a proprietary hydrogen sulfide platform, including lead drug otenaproxesul for opioid alternatives and ATB-352 for acute pain indications.